Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | DPP4 | P27487 | 3/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 2/20 | 0.47 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
| ▸ | AKT2 | P31751 | 2/20 | 0.44 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775830 | 0.93 | HDAC8 (0.68) | HDAC8DPP4DPP7DPP8DPP9 | |
| SCHEMBL4794738 | 0.89 | HDAC8 (0.63) | HDAC8DPP4DPP7DPP8DPP9 | |
| SCHEMBL4905417 | 0.86 | HDAC8 (0.80) | HDAC8DPP4DPP7DPP8DPP9 | |
| SCHEMBL4905399 | 0.86 | HDAC8 (0.80) | HDAC8DPP4DPP7DPP8DPP9 | |
| SCHEMBL4773213 | 0.84 | HDAC8 (0.51) | HDAC8DPP4DPP7DPP8DPP9 | |
| SCHEMBL4773293 | 0.82 | HDAC8 (0.51) | HDAC8DPP4DPP8DPP9MC4R | |
| SCHEMBL4795024 | 0.82 | HDAC8 (0.76) | HDAC8DPP4DPP7DPP8DPP9 | |
| SCHEMBL4909803 | 0.82 | MC4R (0.56) | HDAC8DPP4DPP8DPP9MC4R | |
| SCHEMBL4904798 | 0.82 | HDAC8 (0.48) | HDAC8DPP4DPP8DPP9MC4R | |
| SCHEMBL4779245 | 0.81 | SIGMAR1 (0.55) | HDAC8DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | claimed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | claimed |
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | HDAC8 16/4885DPP4 616/4885DPP7 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.